Actively Recruiting
The Immune Landscape of Epithelial Ovarian Cancer
Led by Oncology Institute of Southern Switzerland · Updated on 2025-11-18
74
Participants Needed
1
Research Sites
310 weeks
Total Duration
On this page
Sponsors
O
Oncology Institute of Southern Switzerland
Lead Sponsor
I
Institute of Oncology Research
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a single center prospective observational study to characterize the immune landscape of newly diagnosed epithelial ovarian cancer (OC). Patients with newly diagnosed epithelial OC will be enrolled in 4 different cohorts: A) Newly diagnosed high grade serous or endometroid OC undergoing primary debulking surgery; B) Newly diagnosed high grade serous or endometroid OC undergoing neoadjuvant chemotherapy (NACT) followed by interval debulking surgery; C) Rare subtypes of epithelial OC (low grade serous, low grade endometrioid, clear cell, mucinous or carcinosarcoma) undergoing primary debulking surgery; D) Rare subtypes of epithelial OC (low grade serous, low grade endometrioid, clear cell, mucinous or carcinosarcoma) undergoing NACT followed by interval debulking surgery. A cohort of women undergoing adnexectomy for benign pathology will be enrolled (cohort E) for comparative analysis. Enrolled patients will be asked to provide the following biological samples at specified time points: archival and fresh tumor tissue, peripheral blood samples, rectal and vaginal swabs, ascites (when present). The main aim of the study is to characterize the immune landscape of epithelial OC in tumor tissue and peripheral blood and correlate the presence of myeloid-derived suppressive cells (MDSCs) and other immune infiltrates and of the systemic immune response with progression free interval (PFI) in epithelial OC.
CONDITIONS
Official Title
The Immune Landscape of Epithelial Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Suspicious diagnosis of epithelial ovarian cancer (histological confirmation required)
- Planned surgical procedure for management of epithelial ovarian cancer or recurrent ovarian cancer treated previously (cohorts A-D)
- 18 years of age or older
- ECOG Performance Status of 2 or less
- Written informed consent
- Indication for adnexectomy for benign gynecological condition (cohort E)
- 18 years of age or older (cohort E)
- ECOG Performance Status of 2 or less (cohort E)
- Written informed consent (cohort E)
You will not qualify if you...
- Other active cancers that could affect study results
- Active autoimmune disease requiring treatment or immune deficiency
- Current chronic treatment with steroids or other immune suppressive agents at study entry
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland, 6500
Actively Recruiting
Research Team
I
Ilaria Colombo, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here